SMS Lifesciences India Ltd. engages in manufacturing and selling of active pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 567 full-time employees. The company went IPO on 2017-08-17. The firm's API products include Ranitidine Hydrochloride (Form-2) USP / Ph.Eur / IP, Famotidine USP / Ph.Eur / IP, Sildenafil Citrate USP / Ph.Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph.Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. The firm's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center at Sanath Nagar in Hyderabad. The firm's wholly owned subsidiary is Mahi Drugs Private limited.

SMSLIFE.NS Profile, Market Tickers and Other

SMSLIFE.NS profile

SMSLIFE.NS market tickers